These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 26027502)

  • 1. Long-Term Survival with Long-Acting Somatostatin Analogues Plus Aggressive Cytoreductive Surgery in Patients with Metastatic Neuroendocrine Carcinoma.
    Deutsch GB; Lee JH; Bilchik AJ
    J Am Coll Surg; 2015 Jul; 221(1):26-36. PubMed ID: 26027502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver.
    Chung MH; Pisegna J; Spirt M; Giuliano AE; Ye W; Ramming KP; Bilchik AJ
    Surgery; 2001 Dec; 130(6):954-62. PubMed ID: 11742323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis.
    Strosberg JR; Yao JC; Bajetta E; Aout M; Bakker B; Hainsworth JD; Ruszniewski PB; Van Cutsem E; Öberg K; Pavel ME
    Endocr Relat Cancer; 2015 Dec; 22(6):933-40. PubMed ID: 26373569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Octreotide long-acting repeatable among elderly patients with neuroendocrine tumors: a survival analysis of SEER-Medicare data.
    Shen C; Shih YC; Xu Y; Yao JC
    Cancer Epidemiol Biomarkers Prev; 2015 Nov; 24(11):1656-65. PubMed ID: 26315553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Octreotide LAR Dosage and Survival Among Elderly Patients With Distant-Stage Neuroendocrine Tumors.
    Shen C; Xu Y; Dasari A; Shih YC; Yao JC
    Oncologist; 2016 Mar; 21(3):308-13. PubMed ID: 26911407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical response of large cell neuroendocrine carcinoma of the lung to perioperative adjuvant chemotherapy.
    Saji H; Tsuboi M; Matsubayashi J; Miyajima K; Shimada Y; Imai K; Kato Y; Usuda J; Kajiwara N; Uchida O; Ohira T; Hirano T; Mukai K; Kato H; Ikeda N
    Anticancer Drugs; 2010 Jan; 21(1):89-93. PubMed ID: 19770636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological, treatment, and prognosis study of 43 gastric neuroendocrine carcinomas.
    Liu DJ; Fu XL; Liu W; Zheng LY; Zhang JF; Huo YM; Li J; Hua R; Liu Q; Sun YW
    World J Gastroenterol; 2017 Jan; 23(3):516-524. PubMed ID: 28210088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endoluminal resection for sessile neoplasia in the GI tract is associated with a low recurrence rate and a high 5-year survival rate.
    Wang AY; Ahmad NA; Zaidman JS; Brensinger CM; Lewis JD; Long WB; Kochman ML; Ginsberg GG
    Gastrointest Endosc; 2008 Jul; 68(1):160-9. PubMed ID: 18577483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. INITIATION OF PATIENTS ONTO LONG-ACTING SOMATOSTATIN ANALOGUE THERAPY FOR NEUROENDOCRINE TUMORS: A SINGLE-CENTER REVIEW OF PRACTICE.
    Tadman M; Charlton P; Jafar-Mohammadi B; Talbot D; Grossman AB
    Endocr Pract; 2018 Feb; 24(2):189-194. PubMed ID: 29466059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
    Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M
    Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term survival of patients treated with octreotide for metastatic well differentiated neuroendocrine carcinoma of the lung.
    Filosso PL; Croce S; Oliaro A; Ruffini E
    J Cardiovasc Surg (Torino); 2000 Oct; 41(5):773-6. PubMed ID: 11149647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-Grade Gastrointestinal Neuroendocrine Carcinoma Management and Outcomes: A National Cancer Database Study.
    Alese OB; Jiang R; Shaib W; Wu C; Akce M; Behera M; El-Rayes BF
    Oncologist; 2019 Jul; 24(7):911-920. PubMed ID: 30482824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Large-cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighteen cases and the efficacy of adjuvant treatment with octreotide.
    Filosso PL; Ruffini E; Oliaro A; Rena O; Casadio C; Mancuso M; Turello D; Cristofori RC; Maggi G
    J Thorac Cardiovasc Surg; 2005 Apr; 129(4):819-24. PubMed ID: 15821649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reappraisal of lymphatic mapping for midgut neuroendocrine patients undergoing cytoreductive surgery.
    Wang YZ; Carrasquillo JP; McCord E; Vidrine R; Lobo ML; Zamin SA; Boudreaux P; Woltering E
    Surgery; 2014 Dec; 156(6):1498-502; discussion 1502-3. PubMed ID: 25456941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut.
    Strosberg J; Gardner N; Kvols L
    Neuroendocrinology; 2009; 89(4):471-6. PubMed ID: 19174605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Octreotide long-acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: a population-based analysis.
    Shen C; Shih YC; Xu Y; Yao JC
    Cancer; 2014 Jul; 120(13):2039-49. PubMed ID: 24676892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metastatic carcinoid tumor: changing patterns of care over two decades.
    Townsend A; Price T; Yeend S; Pittman K; Patterson K; Luke C
    J Clin Gastroenterol; 2010 Mar; 44(3):195-9. PubMed ID: 19609217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy of somatostatin analogs in the treatment of neuroendocrine tumours and paraneoplastic syndromes].
    Sperlongano P; De Falco M; Pisaniello D; Parmeggiani D; Parmeggiani U
    Minerva Endocrinol; 2001 Dec; 26(4):293-5. PubMed ID: 11782719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose octreotide acetate for management of gastroenteropancreatic neuroendocrine tumors.
    Chadha MK; Lombardo J; Mashtare T; Wilding GE; Litwin A; Raczyk C; Gibbs JF; Kuvshinoff B; Javle MM; Iyer RV
    Anticancer Res; 2009 Oct; 29(10):4127-30. PubMed ID: 19846960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses.
    Ferolla P; Faggiano A; Grimaldi F; Ferone D; Scarpelli G; Ramundo V; Severino R; Bellucci MC; Camera LM; Lombardi G; Angeletti G; Colao A
    J Endocrinol Invest; 2012 Mar; 35(3):326-31. PubMed ID: 21757992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.